Chiltern Takes Top Site Rating in CenterWatch Survey For Second Time

April 3, 2017

Chiltern ranked in the top three in the 2017 CenterWatch Global Investigative Site Survey this year. The company also came in as a top-rated CRO in the 2015 survey. The survey asked principal investigators and study coordinators to rate the CROs they worked with during the past two years in six categories. Chiltern was recognized specifically for its open communication, timely drug availability and ranked among the top-three CROs in 17 out of the 37 attributes measured.

“We view our sites as an integral partner. Without them, neither we nor our clients can be successful,” said Jim Esinhart. “With that as our foundation, we are interested in how sites view us when working together… We work hard to try to design our processes around the needs of the site.’

About Chiltern: Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.

Read More